/ Portfolio Companies /
DRIVING HEALTHCARE FORWARD
With an added value that extends beyond capital, our portfolio companies enjoy unprecedented access to a dedicated research and evaluation team boasting deep scientific and commercial backgrounds, as well as to the Medison’s clinical, commercial and regulatory knowledge, and to a wide network of global pharma partners. This comprehensive support helps our portfolio companies streamline the development of breakthrough technologies.
Direct investments in biotech companies across development stages.
Clinical stage biotech company developing therapeutics for the treatment of muscle disorders. | NASDAQ: KROS
Clinical stage biotech company developing novel RNA-modulating drug candidates to treat rare and ultra-rare diseases. | NASDAQ: ELOX
Alpha Tau Medical
Clinical stage company, developing highly potent and conformal Alpha Radiotherapy (Alpha DaRTTM) for solid cancer tumors.
Commercial stage biotech company developing novel cancer immunotherapies.
Clinical stage biotech company developing allogeneic CAR T (AlloCARTTM) therapies for cancer. | NASDAQ: ALLO
Commercial stage biotech company developing ex-vivo autologous gene therapy to address severe and life-threatening inherited disorders. | NASDAQ: ORTX
Clinical stage biotech company developing novel small molecule drugs to extend and improve the lives of patients in areas of high unmet needs
Arqule was fully acquired by Merck & Co. 2019
In 2019, Pontifax and Medison launched a $150M venture lending fund. The fund provides non-dilutive funding to innovative clinical-stage life science companies.
To learn more about Pontifax: www.pontifax.com
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. | NASDAQ: OPNT
Soligenix is a late-stage biopharmaceutical company that develops and commercializes products that treat rare diseases. | NASDAQ: SNGX
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. | NASDAQ: ALNA
CytoReason is an AI company developing a computational model of the human body, accurate enough to start replacing animal and human trials in drug development.
ProQR is a clinical stage biotechnology company dedicated to changing lives by developing unique RNA therapies for rare genetic diseases, specializing in retinal diseases. | NASDAQ: PRQR
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients with cancer greater and more durable benefits than current immuno-oncology treatments. | NASDAQ: FSTX
Vascular Graft Solutions (VGS) is a leading developer of innovative technologies to improve surgical revascularization, vascular reconstruction procedures, and arteriovenous fistula.
Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO) | Euronext Brussels: OXUR